Mathew John M, Mukherji Ashutosh, Saxena Sunil Kumar, Vijayaraghavan Niranjan, Menon Abhilash, Sriharsha Kombathula, Rafi Malu
Department of Radiation Oncology, JIPMER, Pondicherry, India.
Department of Otorhinolaryngology, JIPMER, Pondicherry, India.
Rep Pract Oncol Radiother. 2021 Sep 30;26(5):655-663. doi: 10.5603/RPOR.a2021.0078. eCollection 2021.
Intensity modulated radiotherapy (IMRT) has the perceived advantage of function preservation by reduction of toxicities in the treatment of laryngo-pharyngeal malignancies. The aim of the study was to assess changes in dysphagia from baseline (i.e. prior to start of treatment) at three and six months post treatment in patients with laryngo-pharyngeal malignancies treated with radical radiotherapy ± chemotherapy. Functional assessment of other structures involved in swallowing was also studied.
40 patients were sampled consecutively. 33 were available for final analysis. Dysphagia, laryngeal edema, xerostomia and voice of patients were assessed at baseline and at three and six months after treatment. Radiation was delivered with simultaneous integrated boost (SIB) using volumetric modulated radiation therapy (VMAT). Concurrent chemotherapy was three weekly cisplatin 100 mg/m.
Proportion of patients with dysphagia rose significantly from 45.5% before the start of treatment to 57.6% at three months and 60.6% at six months post treatment (p = 0.019). 67% patients received chemotherapy and addition of chemotherapy had a significant correlation with dysphagia (p = 0.05, r = -0.336). Severity of dysphagia at three and six months correlated significantly with the mean dose received by the superior constrictors (p = 0.003, r = 0.508 and p = 0.024, r = 0.391) and oral cavity (p = 0.001, r = 0.558 and p = 0.003, r = 0.501). There was a significant worsening in laryngeal edema at three and six months post treatment (p < 0.01) when compared to the pre-treatment examination findings with 60.6% of patients having grade two edema at six months. Significant fall in the mean spoken fundamental frequency from baseline was seen at 6 months (p = 0.04), mean fall was 21.3 Hz (95% CI: 1.5-41 Hz) with significant increase in roughness of voice post treatment (p = 0.01).
There was progressive worsening in dysphagia, laryngeal edema and voice in laryngo-pharyngeal malignancies post radical radiotherapy ± chemotherapy.
调强放射治疗(IMRT)在喉咽恶性肿瘤治疗中具有通过降低毒性来保留功能的优势。本研究的目的是评估接受根治性放疗±化疗的喉咽恶性肿瘤患者在治疗后三个月和六个月时吞咽困难相对于基线(即治疗开始前)的变化。还对参与吞咽的其他结构进行了功能评估。
连续抽取40例患者。33例可用于最终分析。在基线以及治疗后三个月和六个月时评估患者的吞咽困难、喉部水肿、口干和嗓音情况。使用容积调强放疗(VMAT)进行同步整合加量(SIB)放疗。同期化疗为每三周一次顺铂100mg/m²。
吞咽困难患者的比例从治疗开始前的45.5%显著上升至治疗后三个月时的57.6%以及六个月时的60.6%(p = 0.019)。67%的患者接受了化疗,化疗的加入与吞咽困难显著相关(p = 0.05,r = -0.336)。治疗后三个月和六个月时吞咽困难的严重程度与咽上缩肌(p = 0.003,r = 0.508以及p = 0.024,r = 0.391)和口腔(p = 0.001,r = 0.558以及p = 0.003,r = 0.501)所接受的平均剂量显著相关。与治疗前检查结果相比,治疗后三个月和六个月时喉部水肿有显著加重(p < 0.01),60.6%的患者在六个月时出现二级水肿。在六个月时观察到平均言语基频相对于基线有显著下降(p = 0.04),平均下降21.3Hz(95%CI:1.5 - 41Hz),治疗后嗓音粗糙度显著增加(p = 0.01)。
根治性放疗±化疗后,喉咽恶性肿瘤患者的吞咽困难、喉部水肿和嗓音情况逐渐恶化。